PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 29, 2008

Primary Completion Date

March 16, 2010

Study Completion Date

June 11, 2012

Conditions
Carcinoma, Non Small Cell Lung
Interventions
DRUG

PF-00299804

PF-00299804 orally at 45 mg daily, on continuous schedule

DRUG

PF-00299804

PF-00299804 orally at 45 mg daily, on continuous schedule

Trial Locations (19)

20892

CCR, National Cancer Institute, Bethesda

30303

Grady Health Systems, Atlanta

30308

Emery University Hospital Midtown, Atlanta

30322

Emory Clinic, Atlanta

Emory University Hospital, Atlanta

Winship Cancer Institute, Atlanta

48201

Karmanos Cancer Institute/Wayne State University, Detroit

48334

Lawrence and Idell Weisberg Cancer Treatment Center, Farmington Hills

80045

Rocky Mountain Lions Eye Institute, Aurora

University of Colorado Hospital, Anschutz Cancer Pavilion, Aurora

University of Colorado Hospital, Anschutz Inpatient Pavilion, Aurora

University of Colorado Hospital, Aurora

91010

City of Hope, Duarte

91030

City of Hope South Pasadena Cancer Center, South Pasadena

91105

City of Hope Medical Group, Pasadena

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY